DEA MATE Opioid and Substance Use for Practitioners

Name: DEA MATE Opioid and Substance Use for Practitioners
Brand: HealthStream, Inc.
SKU: 01t4V000009Cg9LQAS
Price: 149.0 USD
Availability: InStock

Courses: 5 | Credit Hours: 8 | High Quality

This course meets the 8-hour training requirement for Drug Enforcement
Administration (DEA) registered practitioners such as physicians, physician assistants, nurse practitioners, dentists, and others relevant to the Medication Access and Training Expansion (MATE) Act (Section 1263 of the Consolidated Appropriations Act [CAA] of 2023).

This course discusses evidence-based strategies and best practices for preventing, treating, and mitigating substance use disorder (SUD) or opioid use disorder (OUD), as well as legal and ethical considerations related to effective pain management and opioid handling.

.price-ui--loading { display: block !important; opacity: 1 !important; }

$149

stethoscope on top of books with DEA Required badge

DEA MATE Act Required 8-Hour Training for License Renewal

Meet the DEA's new requirement under the Medication Access and Training Expansion (MATE) Act in an online, high-quality and self-paced 8-hour DEA MATE Act course specifically designed for practitioners, including Physicians, PAs, NPs, Pharmacists, Dentists and others.

Read DEA Requirement Letter

Course Topics

Foundations in Opioid Administration: Micro-Certification

Opioids and Pain Management: Micro-Certification

Opioid Misuse: Micro-Certification

Substance Use Disorder: Opioids, Treatment Approaches, and Relapse

Confidentiality of Substance Use Patient Records

Course Objectives

After completion of this course, the participant should be able to:

Recall legal requirements for opioid prescribing and handling.
Apply key recommendations and best practices, restrictions, and requirements for prescribing opioids for pain management.
Specify essential client education and conversations related to use of opioids for pain management, including safety, storage, and disposal information.
Identify how geographic, ethnic, and socioeconomic health disparities and biases affect appropriate and equitable pain assessment, treatment, and management.
Identify the best use of screening tools for substance use disorder (SUD).
Describe how to identify risk for, diagnose, and appropriately treat someone with opioid overdose, opioid use disorder (OUD), or SUD.
Evaluate the process and functions of state Prescription Drug Monitoring Programs (PDMPs).
Identify techniques for building mutual respect between the client, family, and care team responsible for treatment of OUD or SUD.
Explain potential treatment benefits and pitfalls of medication-assisted treatment (MAT) programs to treat OUD or SUD.
List strategies that align with HIPAA or the 42 CFR Part 2 (Final Rule) for maintaining the confidentiality of clients and their protected health information (PHI) while undergoing treatment for OUD or SUD.

Accreditation

HealthStream designates this enduring material for a maximum of 8.0 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity. This educational offering is provided by HealthStream CNE Provider Unit. HealthStream CNE Provider Unit is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. ANCC Provider Number: P0088. This activity is awarded 8.0 contact hours; 0.0 contact hours are in pharmacology.

FAQs

: DEA MATE, or the DEA’s Medication-Assisted Treatment (MAT) Expansion, is a program designed to enhance access to medication-assisted substance use treatment plans for individuals struggling with opioid use disorder. This initiative aims to address the growing opioid crisis by providing healthcare practitioners with the necessary education and resources to effectively implement MAT in their practices. MAT combines the use of medications such as methadone, buprenorphine, and naltrexone with counseling and behavioral therapies, offering a comprehensive approach to treating substance use disorders.
: The DEA 3-day Rule is a regulation that allows practitioners to administer narcotic drugs to a patient for the purpose of relieving acute withdrawal symptoms. This rule permits the dispensing of narcotic medications without a prescription, but only for a maximum of three days. This time frame is intended to provide necessary treatment while a longer-term solution, such as admission into a substance abuse treatment program, is arranged. The rule strictly prohibits any renewals or extensions beyond the three-day period, ensuring that this option is used only as a short-term intervention rather than a prolonged treatment.